viewPreveCeutical Medical Inc.

PreveCeutical Medical stock soars, but company says not aware of reasons behind rally

Shares of the health sciences company soar sharply in both Canada and New York

Medical charts
PreveCeutical is a health sciences company.

PreveCeutical Medical Inc (CSE: PREV) (OTCQB: PRVCF) shares closed sharply higher on Tuesday, but the company said it was not aware of any reason behind the stock's surge.

"At the request of the Investment Industry Regulatory Organization of Canada (IIROC), (the company) confirms that its management is not aware of any undisclosed corporate development or material change to the company or its operations that would account for the recent increase in market activity," a statement said.

Shares of PreveCeutical in Canada closed 50% higher at C$0.06, while its stock in New York settled 53.33% stronger at US$0.46. 

BIG PICTURE: PreveCeutical Medical reaches major milestone in its Australia Sol-Gel research program

PreveCeutical is a health sciences company that develops options for preventive and curative therapies utilizing organic and nature identical products.

The company currently has five research and development programs.

They include a dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a Sol-gel drug delivery program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

The company is based in Vancouver, British Columbia.

Quick facts: PreveCeutical Medical Inc.

Price: 0.055 CAD

Market: CSE
Market Cap: $21.8 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...



PreveCeutical prepares for the final stage of their Sol-Gel program

PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked...

on 27/4/19

2 min read